Savitribai Phule Pune University

विज्ञान एवं प्रौद्योगिकी विभाग
DEPARTMENT OF
SCIENCE & TECHNOLOGY

Technology Enabling Center (TEC)

DST - SPPU

NEWSLETTER

Year 4 Volume 1

Prof. Dr. **Aditya Abhyankar,**
PI – DST-TEC-SPPU
Chief Editor

JAN **2022 – JUNE 2022**

By:
DSTs
Technology Enabling Center (TEC)
SAVITRIBAI PHULE PUNE UNIVERSITY

Prof. Dr. **Nitin Karmalkar,**
Vice Chancellor, SPPU
Chief Patron

DST – Assigned Mentor

Prof. Dr. **K Balasubramanian,**
Professor, Mechanical Engineering
IIT Madras (IITM)

Dr. Krishna Kanth Pulicherla, DST- India

Dr. Mrs. Anita Aggarwal, DST- India

।। यः क्रियावान् स पण्डितः ।।

DST – Mentors – Authorities - Advisors

Introduction: TECHWINGS FROM DST-TEC – Details of the incubatees

DST-TEC at SPPU supported following incubates during Jan to June 2022.

Sr No	Name of the company/start up	Description of support provided at DST-TEC at SPPU
1	Pm Planet Innovation pvt ltd, Mystro Engineers, Tap Engineers, Leotech, Unicorn CNC, Astrix Media Pvt Ltd, Minander Tech, Divy IT Solutions, Akash Construction, Prism Dome Tech	Connects and access market, Networking and mentoring (B2B and B2C)

Activities carried under DST-TEC at SPPU during Jan 2022 – June 2022:

Following table presents a summary of the activities carried out under DST-TEC at SPPU during Jan 2022 – June 2022:

Date	Activity	Outcomes
18th January 2022	**Online workshop on Mechanical Ventilation: Introduction to Respiratory System**	65+ participants from various **medical** institutes participated, feedback was good.
February 2022	**11 IPR awareness online sessions**	300+ stakeholders participated, Introduction to Intellectual Property Rights and its relevance in current scenario, Introduction to Designs In IPR, Introduction to Trademark and Copyright law
8th March2022	**On-line IoT workshop for POCs**	78+ participants, hands on skills were imparted for designing and developing IoT (Internet of Things) skillsets for quick creation of POCs. Participants gave positive feedback as these skill sets will help them convert their ideation into prototype systems.
4th May 2022	**Pre-incubation 4.0**	160+ stakeholders, pre-incubation activity, ideation, quizzes, cash prizes. 7 groups selected for furtherance.
May 2022	**4 On-line IPR workshops**	17+ incubated participants, Trademark and Copyright filing procedure – Do's and Don'ts, Patent application procedure, Introduction to Designs In IPR, Trademark infringements and how to deal with them
6th June 2022	**On-line session on IT Healthcare**	41+ participants, AI applications in Healthcare, Digital technology & Medical mentoring, Improving patient safety using software, Digital platforms for Quality Improvement

Glimpses of various activities conducted:

Various Activities conducted from January to June

Various activities conducted from Jan to June 2022. All the activities were conducted in hybrid online + offline mode as per norms. This gave clear idea on Technology Infra-footprint of SPPU TEC, current associations, start-up space and corporate quadrants to the potential stakeholders.

Success story 4.1 incubated at TEC:

Uppraising Industry partners

The New drugs and Clinical trials rules 2019 (New rules) were introduced on by Government of India. These are responsible for the changes in responsibilities of the ethics committee. And Pharmaceutical Industries are bound to follow these rules through Central Licensing Authority (CLA).

The New Drugs and Clinical Trials Rules (NDCT)2019 (New rules), i.e. GSR 227 (E) are introduced by Indias Ministry of Health and Family Welfare (MoHFW).

The Drugs Controller, India, appointed by the Central Government in the MoHFW has been designated as the Central Licensing Authority under the NDCT Rules, to act as the nodal entity for licensing and approvals under these rules.

Ethics Committee: Under the NDCT Rules, an Ethics Committee is required to be set up and registered by whoever intends to conduct clinical trials or bioavailability studies or bioequivalence studies.

The study/ trial can be conducted only with the approval of this Committee, whose registration with the Central Licensing Authority will be valid for a period of five years. In case of any serious adverse event during a clinical trial or bioavailability or bioequivalence study, the Ethics Committee is required to analyze the relevant documents pertaining to such event and forward its report to the Central Licensing Authority.The Application for permission to conduct clinical trials is required to be submitted to the Central Licensing Authority in Form CT-04. Further, the application must be accompanied with information and Documents.

- Mrs. Shweta Atkar

NDCT Rules for Manufacture of New Drugs for Clinical Trial needs:

Permission of the Central Licensing Authority

To manufacture a new drug for conducting

- clinical trial
- bioavailability
- bioequivalence
- To study or for examination,
- To test and analyze
- To label requirements and varied conditions

For a valid period of three years.

The NDCT Rules are applicable to, and regulate, all new drugs, investigational new drugs for human use, clinical trials, bioequivalence studies, bioavailability studies and Ethics Committees.

Contact: **DST – TEC (Technology Enabling Center) at Savitribai Phule Pune University Department of Technology,** Ganeshkhind, Shivaji Nagar, Pune – 411007, MH, India
https://goo.gl/maps/CMPga7dJLeRnqtrD7
http://www.unipune.ac.in/dot/tech_webfiles/DST-TEC.htm
Phone: +91-020-25601270, Email: hodtech@unipune.ac.in

---------- ******** **End of the Newsletter** ********** ----------